Maintenance therapy with certolizumab pegol for Crohn's disease

Article Abstract:

A randomized trial involving maintenance and withdrawal therapy with certolizumab pegol in patients with moderate-to-severe Crohn's disease is presented. Results show that patients who had a response to induction therapy with 400 mg of certolizumab pegol are more likely to have a maintained response and a remission at 26 weeks with continued treatment than with a switch to placebo.

Certolizumab pegol (Medication)

---

Certolizumab pegol for the treatment of Crohn's disease

Article Abstract:

A study evaluates the efficacy of certolizumab pegol in adults with moderate-to-severe Crohn's disease. Findings suggest that induction and maintenance therapy with certolizumab pegol is associated with a modest improvement in response rates, as compared with placebo, but there is no significant improvement in remission rates.

HEALTH SERVICES, All Other Miscellaneous Ambulatory Health Care Services, Disease Testing Programs, Health aspects, Drugs, Drug evaluation, Certolizumab pegol (Medication)

---

Natalizumab induction and maintenance therapy for Crohn's disease

Article Abstract:

Two controlled experiments are carried out to examine natalizumab as induction and maintenance treatments in patients suffering from active Crohn's disease. Findings indicate that for Crohn's disease, induction therapy with natalizumab produced small insignificant improvements in response and remission rates.

United Kingdom, Science & research, Research, Natalizumab

Similar abstracts:

• Abstracts: Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis
• Abstracts: Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. Zoledronic acid and clinical fractures and mortality after hip fracture
• Abstracts: Long-term vasodilator therapy in patients with severe aortic regurgitation. Long-term follow-up of idiopathic chronic pericardial effusion
• Abstracts: Mental health research emerges from hurricane ruin. Scientists stumped by dual push for open access, secrecy. Race-based heart drug might stall search for better markers
• Abstracts: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. The medical management of depression

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.